

Supplementary Materials for

***Bacteroides uniformis* and its preferred substrate,  $\alpha$ -cyclodextrin, enhance endurance exercise performance in mice and human males**


Hiroto Morita *et al.*

Corresponding author: Shinji Fukuda, [sfukuda@sfc.keio.ac.jp](mailto:sfukuda@sfc.keio.ac.jp)

*Sci. Adv.* **9**, eadd2120 (2023)  
DOI: 10.1126/sciadv.add2120

**This PDF file includes:**


Figs. S1 to S10  
Tables S1 to S3



**Fig. S1: Relative abundances of *Escherichia*, *Lachnospira*, and *Sutterella* showed differences between the athlete and non-athlete groups but did not correlate with the 3,000-m race time.**





**A**, Box-and-whisker plots of the relative abundances of the genera with  $|\text{Linear discriminant analysis score}| > 2$  in the linear discriminant analysis effect size (LEfSe) analysis of the athlete and non-athlete groups. The relative abundance of *Bacteroides* is depicted in Figure 1. The center line represents the median in the box plots, and the box boundaries correspond to the 25th and 75th percentiles. The whiskers represent the most extreme values within 1.5 times the interquartile range below the 25th percentile and above the 75th percentile. The Mann–Whitney *U*-test was used to determine the statistical significance. **B**, Scatterplot of the relative abundances of *Prevotella*, *Escherichia*, *Lachnospira*, and *Sutterella* in the athlete group and the 3,000-m race time. The dotted line shows the regression line. Correlations were established using the Pearson correlation coefficient. **C**, Correlations of blood parameters with the relative abundances of *Prevotella*, *Escherichia*, *Lachnospira*, *Sutterella*, and *Bacteroides* in the athlete group. The blood parameters selected in this study are associated with anemia and may affect long-distance

running capacity. The creatine phosphokinase (CPK) levels reflect the degree of muscle injury. Each Pearson correlation coefficient is shown in the heatmap. For all parameters except the 3,000-m race time, the sample size was as follows: athlete group,  $n = 43$ ; non-athlete group,  $n = 8$ . For the 3,000-m race time, the sample size was as follows: athlete group,  $n = 25$ . Twenty-three of 48 athletes refused to participate in the measurement of the race time. \*  $P < 0.05$ .  
MCV: mean corpuscular volume; MCH: mean corpuscular hemoglobin; CPK: creatine phosphokinase; MCHC: mean corpuscular hemoglobin concentration; Hb: hemoglobin; RBC: red blood cell.




**Fig. S2: Abundance of *B. caccae*, *P. dorei*, *B. eggerthii*, *B. thetaiotaomicron*, and *P. vulgatus* in the athlete group was higher than in the non-athlete group but did not correlate with the 3,000-m race time.**

**A**, Box-and-whisker plots of the log<sub>10</sub> copy numbers of 16S rRNA-encoding gene of *Bacteroides* and *Phocaeicola* species determined using species-specific qPCR in the athlete and non-athlete groups. The center line represents the median in the box plots, and the box boundaries represent the 25th and 75th percentiles. The whiskers represent the most extreme values within 1.5 times the interquartile range below the 25th percentile and above the 75th percentile. The Mann–Whitney *U*-test was used for the assessment of statistical significance. **B**, Correlations between the 3,000-m race time and log<sub>10</sub> copy numbers of 16S rRNA-encoding gene of the five species with significantly higher copy numbers in the athlete group than in the non-athlete group. Correlations were established using the Pearson correlation coefficient. For the comparison of the copy numbers of the species: athlete group, *n* = 48; non-athlete group, *n* = 10. For the analysis of the correlation with the 3,000-m race time: athlete group, *n* = 25.



**Fig. S3: Supplementation with flaxseed lignans or  $\alpha$ CD did not alter the human gut microbiome.**


**A–C**, Chao1 estimate (**A**), phylogenetic distance (PD) of the whole tree (**B**), and Shannon diversity index (**C**) of the placebo group, flaxseed lignan (FL) group, and  $\alpha$ -cyclodextrin ( $\alpha$ CD) groups. The box-and-whisker plots illustrate the distribution of values within each group. In the box plots, the center line represents the median, and the box boundaries represent the 25th and 75th percentiles. The whiskers represent the most extreme values within 1.5 times the interquartile range below the 25th percentile and above the 75th percentile. The statistical significance of the group differences was analyzed using a two-sample *t*-test using Monte Carlo permutations. **D, E**, Fecal microbiome profiles of the placebo and FL groups (**D**) and the placebo and  $\alpha$ CD groups (**E**). Principal coordinate analysis plots with weighted or unweighted UniFrac distances showed no differences between two treatment groups and placebo. The statistical significance of the differences between the groups was analyzed using permutational multivariate analysis of variance (PERMANOVA). **F**, Phylum-level fecal microbiota composition of the placebo and treated groups. The mean relative abundance of each bacterial phylum is shown in the pie charts. The sample size was as follows: Placebo group,  $n = 11$ ; FL group,  $n = 10$ ;  $\alpha$ CD group,  $n = 10$ .



**Fig. S4: In the randomized, double-blind, placebo-controlled, parallel-group study, ratings of perceived exertion (RPE) in the  $\alpha$ CD and placebo groups were lower after 8 weeks of supplementation than at baseline.**

Values of an individual's RPE were measured with Borg's RPE Scale after a 50-min constant-load bike exercise session. The box-and-whisker plots illustrate the distribution of values within each group. In the box plots, the center line represents the median, and the box boundaries represent the 25th and 75th percentiles. The whiskers represent the most extreme values within 1.5 times the interquartile range below the 25th percentile and above the 75th percentile.


Statistical significance of the differences between groups (placebo group vs. FL group or  $\alpha$ CD group) and within groups (0 weeks vs. 4 or 8 weeks) were analyzed using the Mann-Whitney *U*-test and Wilcoxon signed-rank test, respectively. The sample size was as follows: Placebo group,  $n = 11$ ; FL group,  $n = 10$ ;  $\alpha$ CD group,  $n = 10$ .




**Fig. S5: In the randomized, double-blind, placebo-controlled, parallel-group study, the  $\dot{V}O_{2max}$  and ventilatory threshold (VT) showed no significant differences.**


$\dot{V}O_{2max}$  (A) and VT (B) of the participants in placebo, FL, and  $\alpha$ CD groups. No significant differences were observed between the placebo and two treated groups, or within groups. The box-and-whisker plots illustrate the distribution of values within each group. In the box plots, the center line represents the median, and the box boundaries represent the 25th and 75th percentiles. The whiskers represent the most extreme values within 1.5 times the interquartile range below the 25th percentile and above the 75th percentile. Statistical significance of the differences between groups (placebo vs. FL or  $\alpha$ CD group) and within groups (-4 weeks vs. 9 weeks) was analyzed using an unpaired *t*-test and a paired *t*-test, respectively. The sample size was as follows: Placebo group,  $n = 11$ ; FL group,  $n = 10$ ;  $\alpha$ CD group,  $n = 10$ .





**Fig. S6: In the randomized, double-blind, placebo-controlled, parallel-group study, no significant differences in muscle mass were found between baseline (0 weeks) and at 4 and 8 weeks, but body fat mass in the  $\alpha$ CD group was slightly higher at 8 weeks than at baseline.** Muscle mass (A) and body fat mass (B) of the participants in the placebo, FL, and  $\alpha$ CD groups. The box-and-whisker plots illustrate the distribution of values within each group. In the box plots, the center line represents the median, and the box boundaries represent the 25th and 75th percentiles. The whiskers represent the most extreme values within 1.5 times the interquartile range below the 25th percentile and above the 75th percentile. Statistical significance of the differences in muscle mass between groups (placebo vs. FL or  $\alpha$ CD group) and within groups (0 weeks vs. 4 or 8 weeks) was analyzed using an unpaired and a paired *t*-test, respectively. The body fat mass was analyzed using the Mann–Whitney *U*-test and Wilcoxon signed-rank test. The sample size was as follows: Placebo group,  $n = 11$ ; FL group,  $n = 10$ ;  $\alpha$ CD group,  $n = 10$ .













**Fig. S7: Hematological parameters at baseline (0 weeks), 4, and 8 weeks in the randomized, double-blind, placebo-controlled, parallel-group study.**

The levels of creatinine (A), creatine phosphokinase (B), glucose (C), lactate (D), and lactate dehydrogenase (E) were measured before and immediately after, and 60 min after 50 min of constant-load exercise performed after 0, 4, and 8 weeks of supplementation. The levels of









hormones (**F–H**), free fatty acids (**I**), diacron-reactive oxygen metabolites (**J**), and interleukin-6 (**K**) were measured before and immediately after the constant-load exercise. The box-and-whisker plots illustrate the distribution of values within each group. In the box plots, the center line represents the median, and the box boundaries represent the 25th and 75th percentiles. The whiskers represent the most extreme values within 1.5 times the interquartile range below the 25th percentile and above the 75th percentile. Statistical significance of the differences between groups (placebo vs. FL or  $\alpha$ CD group) and within groups (0 weeks vs. 4 or 8 weeks) was analyzed using the Mann–Whitney *U*-test and Wilcoxon signed-rank test, respectively. The sample size was as follows: Placebo group,  $n = 11$ ; FL group,  $n = 10$ ;  $\alpha$ CD group,  $n = 10$ . Bef.: before 50 min of constant-load exercise; Aft.: immediately after 50 min of constant-load exercise; 60 min aft.: 60 min after 50 min of constant-load exercise.






Placebo group  
FL group  
αCD group





Placebo group  
FL group  
αCD group




**Fig. S8: Blood amino acid levels at baseline (0 weeks), 4 weeks, and 8 weeks in the randomized, double-blind, placebo-controlled, parallel-group study.**

Blood amino acid levels were measured before and immediately after 50 min of constant-load exercise performed after 0, 4, and 8 weeks of supplementation. The box-and-whisker plots illustrate the distribution of values within each group. In the box plots, the center line represents




the median, and the box boundaries represent the 25th and 75th percentiles. The whiskers represent the most extreme values within 1.5 times the interquartile range below the 25th percentile and above the 75th percentile. Statistical significance of the differences between groups (placebo vs. FL or  $\alpha$ CD group) and within groups (0 weeks vs. 4 or 8 weeks) was analyzed using an unpaired *t*-test or the Mann–Whitney *U*-test, and a paired *t*-test or the Wilcoxon signed-rank test, respectively. The statistical tests were selected based on the outcomes of the normality test using the Shapiro–Wilk test. The sample size was as follows: Placebo group,  $n = 11$ ; FL group,  $n = 10$ ;  $\alpha$ CD group,  $n = 10$ .

Bef.: before 50 min of constant-load exercise; Aft.: immediately after 50 min of constant-load exercise.



**Fig. S9: Relative abundance of the genus *Bacteroides* was increased in the FL- and  $\alpha$ CD-fed mice, with  $\alpha$ CD increasing the abundance of *Bacteroides* specifically.**

**A, D**, Box-and-whisker plots showing the relative abundance of *Bacteroides* in the groups fed a diet containing 5% (w/w) FL or  $\alpha$ -CD and their respective control diet-fed groups as determined by 16S rRNA-encoding gene amplicon sequencing with the MiSeq platform ( $n = 8$  for the FL group and associated control group,  $n = 10$  for the  $\alpha$ CD group and associated control group). In the box plots, the center line represents the median, and the box boundaries represent the 25th and 75th percentiles. The whiskers represent the most extreme values within 1.5 times the interquartile range below the 25th percentile and above the 75th percentile. The Mann–Whitney *U*-test was used for the statistical analysis. **B, E**, LEfSe analysis comparing the FL or  $\alpha$ CD group with the associated control group using genus-level microbial composition data. All genera with | Linear discriminant analysis score |  $> 2$  in each group are displayed in this figure. **C, F**, Genus-level fecal microbiota composition of the FL or  $\alpha$ CD group with the associated control group. The mean relative abundance of each bacterial genus is shown in the pie charts.



**Fig. S10: Metabolite concentrations, mRNA levels related to energy acquisition, and glycogen content in murine muscle were comparable among the four groups.**

**A**, The metabolite concentrations related to energy acquisition in murine quadriceps femoris samples from the PBStra<sup>-</sup> ( $n = 10$ ), PBStra<sup>+</sup> ( $n = 10$ ), BUltra<sup>-</sup> ( $n = 10$ ), and BUltra<sup>+</sup> ( $n = 10$ ) groups, determined using capillary electrophoresis time-of-flight mass spectrometry (CE-TOFMS). A heatmap depicts the Z-scores of metabolites involved in energy metabolism, which were calculated from the quantitative values. Individual mice are represented as columns. The  $q$ -

value of each metabolite between each group is shown on the right side. Statistical significance of the differences between groups was analyzed using Student's *t*-tests with Benjamini–Hochberg false discovery rate correction. **B**, Box-and-whisker plots of the mRNA levels of four genes related to glycolysis (*Hk1*, *Hk2*, *Pygm*, and *Glut4*) and *Pgc1α* in the quadriceps femoris samples of the PBStr<sup>–</sup> (*n* = 10), PBStr<sup>+</sup> (*n* = 10), BUtr<sup>–</sup> (*n* = 10), and BUtr<sup>+</sup> (*n* = 10) mice measured by reverse transcription qPCR. **C**, Glycogen content in the murine quadriceps femoris samples from the PBStr<sup>–</sup> (*n* = 10), PBStr<sup>+</sup> (*n* = 10), BUtr<sup>–</sup> (*n* = 10), and BUtr<sup>+</sup> (*n* = 10) groups. In the box plots, the center line represents the median, and the box boundaries represent the 25th and 75th percentiles. The whiskers correspond to the most extreme values within 1.5 times the interquartile range below the 25th percentile and above the 75th percentile. Statistical significance of the differences among groups was analyzed using the Tukey–Kramer test (*HK2*, *Pygm*, and *Pgc1α*) or Steel–Dwass test (*Hk1*, *Glut4*, and glycogen content). The statistical tests were selected based on the outcomes of the normality test using the Shapiro–Wilk test.

PBStr<sup>+</sup>: PBS-administered mice subjected to exercise; PBStr<sup>–</sup>: PBS-administered mice not subjected to exercise; BUtr<sup>+</sup>: *B. uniformis*-administered mice subjected to exercise; BUtr<sup>–</sup>: *B. uniformis*-administered mice not subjected to exercise; G6P: glucose-6-phosphate; F6P: fructose 6-phosphate; PEP: phosphoenolpyruvate; 3PG: 3-phosphoglycerate; 2PG: 2-phosphoglycerate.

**Table S1. Baseline data of participants included in the randomized, double-blind, placebo-controlled, parallel-group human study with FL or  $\alpha$ CD as test supplements.**

	Placebo ( <i>n</i> = 11)	FL group ( <i>n</i> = 10)	$\alpha$ CD group ( <i>n</i> = 10)	<i>P</i> -value <sup>1)</sup>	
				Placebo vs. FL group	Placebo vs. $\alpha$ CD group
Age (years)	36.3 ± 9.6	33.9 ± 10.0	34.5 ± 10.9	0.59	0.70
Weight (kg)	64.01 ± 9.68	63.12 ± 6.34	67.76 ± 7.54	0.81	0.34
Body mass index (kg/m <sup>2</sup> )	22.01 ± 2.43	21.53 ± 1.67	22.23 ± 2.43	0.61	0.84
Heart rate (bpm)	72.5 ± 9.8	70.5 ± 13.0	69.1 ± 9.4	0.70	0.43
VO <sub>2</sub> max (mL/kg/min)	46.40 ± 6.45	43.20 ± 6.83	45.67 ± 8.66	0.28	0.83

These data were collected before supplementation.

Mean ± standard deviation

<sup>1</sup> Two-tailed unpaired *t*-test

**Table S2. Primers and probes used for quantitative real-time PCR for *Bacteroides* and *Phocaeicola* species.**

Target	Primer name	Sequence (5'-3')	Probe name	Sequence (5'Fam-3'Tam)	Reference
<i>B. caccae</i>	B.cac-TaqMan-F	AAACCCATACGCCGCAAG	B.cac-TaqMan-Prb	TGTGAAGGTGCTGCATGGTTGTCGT	49
	B.cac-TaqMan-R	GACACCTCACGGCACGAG			
<i>P. coprocola</i>	BaCOP-F	TATGGTGAGATTGCATGATGG	-		50
	BaCOP-R	ATGAACGTCAGTTACAGTTTAGCAA	-		
<i>P. coprophilus</i>	BaCPP-F	GGGTTGTAAACTTCTTTGTGC	-		50
	BaCPP-R	GCCTCAACCGTACTCAAGGT	-		
<i>P. dorei</i>	BaDOR-F	GGAACGGTTCAGCTAGCAATA	-		50
	BaDOR-R	AGTCTTGTCAGAGTCTCAGCATC	-		
<i>B. eggerthii</i>	B.egg-TaqMan-F	CCCGATAGTATAGTTTTCCGC	B.egg-TaqMan-Prb	TTCGGTTATCGATGGGGATGCGTTC	49
	B.egg-TaqMan-R	TCTCTCAGAACCCCTATCCAT			
<i>B. finegoldii</i>	BaFIN-F	CCGGATGGCATAGGATTGTC	-		50
	BaFIN-R	CGTAGGAGTTTGGACCGTGT	-		
<i>B. fragilis</i>	FW3	AGGATTCGGTAAAGGATGG	-		This study
	RV3	GTCAGGCTAGCGCCATT	-		
<i>B. intestinalis</i>	BaINT-F	AGCATGACCTAGCAATAGGTTG	-		50
	BaINT-R	ACGCATCCCCATCGATTAT	-		
<i>P. plebeius</i>	BaPLE-F	ATCATTAAAGATTTATCGGTGTACG	-		50
	BaPLE-R	ACTTTCACAGCTGACTTAACGAC	-		
<i>B. stercoris</i>	B.ste-TaqMan-F	GCTTGCTTTGATGGATGGC	B.ste-TaqMan-Prb	CCAACCTGCCGACAACACTGGGATA	49
	B.ste-TaqMan-R	CATGCGGGAAACTATGCC	-		
<i>B. thetaiotaomicron</i>	B.the-TaqMan-F	GCAAACCTGGAGATGGCGA	B.the-TaqMan-Pro	TCGATGGGGATGCGTTCCATTAGG	49
	B.the-TaqMan-R	AAGGTTTGGTGAGCCGTTA	-		
<i>B. uniformis</i>	B.uni-TaqMan-F	TCTCCGCATGGTAGAACTATTA	B.uni-TaqMan-Prb	CGTTCATTAGGTTGTTGGCGGGG	49
	B.uni-TaqMan-R	ACCGTGTCTCAGTTCCAATGTG	-		
<i>P. vulgatus</i>	B.vul-TaqMan-F	CGGGCTTAAATTGCAGATGA	B.vul-TaqMan-Prb	TGAAAGCCGTAAGCCGCAAGG	49
	B.vul-TaqMan-R	CATGCAGCACCTTCACAGAT	-		

The TaqMan probes were labeled with the fluorescent dye 6-carboxyfluorescein (FAM) at the 5' end and 6-carboxytetramethylrhodamine (TAMRA) at the 3' end.

**Table S3. Composition of supplements (daily dose) used in the randomized, double-blind, placebo-controlled, parallel-group human study with FL or  $\alpha$ CD as test supplements.**

	FL supplement (mg)	$\alpha$ CD supplement (mg)	Placebo (mg)
FL <sup>1)</sup>	200.1	0.0	0.0
$\alpha$ CD <sup>2)</sup>	0.0	200.1	0.0
Maltitol	487.1	487.1	687.2
Tricalcium phosphate	19.4	19.4	19.4
Hydroxypropyl cellulose	9.0	9.0	9.0
Calcium stearate	30.0	30.0	30.0
Starch	3.0	3.0	3.0
Silicon dioxide	1.5	1.5	1.5

<sup>1</sup> NIPPON flaxseed lignans (Nippon Flour Mills, Tokyo, Japan)

<sup>2</sup> Dextypearl- $\alpha$  (Ensuiko Sugar Refining, Tokyo, Japan)